In vivo I-123 IBZM SPECT imaging of striatal dopamine 2 receptor occupancyin schizophrenic patients

Citation
C. Barnas et al., In vivo I-123 IBZM SPECT imaging of striatal dopamine 2 receptor occupancyin schizophrenic patients, PSYCHOPHAR, 157(3), 2001, pp. 236-242
Citations number
49
Categorie Soggetti
Neurosciences & Behavoir
Journal title
Volume
157
Issue
3
Year of publication
2001
Pages
236 - 242
Database
ISI
SICI code
Abstract
Rationale: Single photon emission computed tomography (SPECT) using I-123 i odobenzamide (IBZM) as tracer substance has been shown to be a useful tool to visualize dopamine 2 (D2) receptor occupancy. Objectives: We investigate d the striatal D2 receptor occupancy of zotepine which is referred to the c lass of atypical antipsychotic drugs. Methods: I-123 IBZM and SPECT were us ed to visualize striatal dopamine 2 (D2) receptor occupancy in zotepine-tre ated schizophrenic patients. Two groups of schizophrenic patients receiving either 150 mg/day zotepine (n=6) or 300 mg/day (n=6) underwent examination . For the quantification of striatal D2 receptor occupancy, striatal IBZM b inding in patients treated with antipsychotics was compared to untreated he althy controls (n=8) reported earlier. Results: Zotepine led to a mean over all striatal D2 receptor occupancy of 73%. Patients with 150 mg daily showe d a significantly lower occupancy (65.8%, SD=6.2) than patients with 300 mg /day (77.8%, SD=10.7; P <0.05). No clinically relevant extrapyramidal side effects occurred during treatment with zotepine. Conclusions: There was no correlation between the degree of striatal D2 receptor occupancy and clinic al improvement.